Colorectal Cancer Screening Market Size, Share, Opportunities, And Trends By Screening Test (Flexible, Sigmoidoscopy, Stool-based Tests, CT Colonography, Colonoscopy, Others), By End-User (Independent Diagnostic Labs, Hospitals, Others), And By Geography - Forecasts From 2023 To 2028

The colorectal cancer screening market was valued at US$1.639 billion in 2021 and is expected to grow at a CAGR of 5.55% during the forecast period.

The noncancerous growth known as a polyp, which can appear on the inner wall of the colon or rectum as people age, is where colorectal cancer most frequently develops. The higher prevalence rate of colorectal cancer due to changing lifestyles, diabetes, and obesity are major growth drivers of the colorectal cancer screening market. Moreover, the increasing smoking culture among people coupled with the growing older population is also expected to increase the risk of colon cancer thereby propelling the colorectal cancer screening market. The increasing awareness about the adverse effects of colorectal cancer and product launches by the market players resulting in more accessibility are further contemplated to augment the colorectal cancer screening market.

Higher Prevalence of Colorectal Cancer

The rising colorectal cancer cases indicate the need for screening and thus contribute positively to the colorectal cancer screening market. With more than 1.9 million cases identified, colorectal cancer was the third most frequent cancer type in the world in 2020, according to the WHO. A projected 153,020 new cases of colorectal cancer (CRC) will be identified in the US in 2023, and 52,550 deaths are estimated as per the American Cancer Society. 

Changing Lifestyle and Diet

A normal Western diet that is high in fat and calories and poor in fiber may be linked to colon and rectal cancer and Colon cancer is more prone to occur in those who are inactive. According to NCBI, the average amount of time spent sitting each day is 7.7 hours for adults in America and 8.3 hours for the Korean population. According to the WHO, over 80% of young people worldwide don't participate in enough physical activity leading to numerous serious health issues including colorectal cancer. Therefore, the adoption of a sedentary lifestyle is expected to aid the colorectal cancer screening market.

Growing Prevalence of Smoking among Population

A significant risk factor for colorectal cancer (CRC) is cigarette smoking. Smoking was found to dramatically increase the risk of CRC formation in animal models as well as CRC incidence and mortality in humans, according to studies by the NCBI.  According to the WHO, 36.7% of all males and 7.8% of all women consumed tobacco worldwide in 2020, making up 22.3% of the global population.  In the UK, there were 6.9 million adult smokers in 2021 equating to 13.3% of adults (aged 18+) according to Cancer Research UK. This huge population engaged in smoking and tobacco indicates higher cases of colorectal cancer cases shortly thus widening the colorectal cancer screening market.

Rising Older Population and Chronic Inflammatory Diseases

The majority of instances affect persons over 50 years of age. The Mayo Clinic reports that colon cancer rates among persons under 50 have been rising. According to the American Cancer Society, 80,010 out of a total of 147,950 colorectal cancer cases were reported in individuals aged 65 years or above i.e., around 50% of total cases. The rising older population is therefore contemplated to bolster the colorectal cancer screening market. For instance, people aged 60 years or above are projected to reach 1.4 billion by 2030 from 1 billion in 2020 according to the WHO estimates.

Increased Awareness about Colorectal Cancer

Multiple campaigns to increase awareness among people coupled with technological innovation are positively driving the colorectal cancer screening market. For instance, US people aged 45 years or older are educated about the value of routine colorectal cancer screenings as part of the CDC's Screen for Life: National Colorectal Cancer Action Campaign. Moreover, in April 2023, the International Agency for Cancer Research published an inaugural report under its Can5 initiative on cancer screening in five continents.

North America is Expected to Grow Significantly

The North American region is expected to hold a significant share of the colorectal cancer screening market during the forecast period. Various factors attributed to such a share are an educated population, government programs, and a higher prevalence of colorectal-causing factors such as smoking and a sedentary lifestyle. For instance, Around 1,600 American teenagers under the age of 18 light up their first cigarette every day, and 16 million additional people suffer from a serious ailment brought on by smoking as per the CDC data. Moreover, the presence of major market leaders such as Exact Science Corporation, and Polymedco Inc. are further expected to aid the colorectal cancer screening market.

Major Market Players

• Exact Science Corporation is a US-based molecular diagnostics company that specializes in detection of early-stage cancers. Cologuard is a stool DNA-bases colorectal cancer screening test offered by the company and it is also developing a blood-based screening method for colorectal cancer.
• Eiken Chemical Co. Ltd. is one of the leading clinical testing companies. The company launched a fully automated fecal immunochemical test OC-SENSOR Ceres™ in November 2022.

Key Market Developments

• In March 2023, in association with CPCRN and NACCD, the CDC introduced a tool for improving the quality of cancer screening for breast, cervical, and colorectal cancers. This package intends to assist community initiatives to boost cancer screening rates and enhance the number of lives saved.
• In February 2023, Sanora Quest Labs introduced InSure ONE, its first colorectal cancer home screening kit. In fecal samples, it looks for human hemoglobin to check for lower gastrointestinal bleeding, which could be a symptom of colon cancer.
• In May 2022, with just a quick blood draw, Guardant Health introduced the Shield test for colorectal cancer. It doesn't require any more time, anesthesia, specific preparation, or dietary adjustments. It recognizes early indications of CRC signals in the blood. 

Colorectal Cancer Screening Market Scope:

 

Report Metric	Details
Market Size Value in 2021	US$1.639 billion
Growth Rate	CAGR of 5.55% from 2021 to 2028
Base Year	2021
Forecast Period	2023 – 2028
Forecast Unit (Value)	USD Billion
Segments Covered	Screening Test, End-User, and Geography
Regions Covered	North America, South America, Europe, Middle East and Africa, Asia Pacific
Companies Covered	Eiken Chemical Co. Ltd, Epigenomics Inc., Exact Sciences Corporation, Polymedco Inc, Hemosure Inc., F. Hoffmann-La Roche AG, QuidelOrtho Corporation, Siemens Healthineers AG, Sysmex Corporation, Olympus Corporation
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Screening Test
  • Flexible Sigmoidoscopy
  • Stool-based Tests
  • CT Colonography
  • Colonoscopy
  • Others
• By End-User
  • Independent Diagnostic Labs
  • Hospitals
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

1.  INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. COLORECTAL CANCER SCREENING MARKET, BY SCREENING TEST

5.1. Introduction

5.2. Flexible Sigmoidoscopy 

5.3. Stool-based Tests

5.4. CT Colonography

5.5. Colonoscopy 

5.6. Others

6. COLORECTAL CANCER SCREENING MARKET, BY END USERS

6.1. Introduction

6.2. Independent Diagnostic Labs

6.3. Hospitals

6.4. Others

7. COLORECTAL CANCER SCREENING MARKET, BY GEOGRAPHY

7.1. Introduction

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Others

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Spain

7.4.5. Others

7.5. The Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. UAE

7.5.3. Israel

7.5.4. Others

7.6. Asia Pacific

7.6.1. Japan

7.6.2. China

7.6.3. India

7.6.4. South Korea

7.6.5. Indonesia

7.6.6. Thailand

7.6.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

9. COMPANY PROFILES

9.1.  Eiken Chemical Co. Ltd

9.2. Epigenomics Inc.

9.3. Exact Sciences Corporation

9.4. Polymedco Inc

9.5. F. Hoffmann-La Roche AG

9.6. QuidelOrtho Corporation

9.7. Siemens Healthineers AG

9.8. Sysmex Corporation

9.9. Olympus Corporation

Eiken Chemical Co. Ltd

Epigenomics Inc.

Exact Sciences Corporation

Polymedco Inc

Hemosure Inc.

F. Hoffmann-La Roche AG

QuidelOrtho Corporation

Siemens Healthineers AG

Sysmex Corporation

Olympus Corporation